Top 10 Sales KPIs for Commercial Specialty Pharmacy in 2027

1LDD Attach Rate KPI

LDD attach rate ranks first because 65-75% of new specialty launches in 2026-2027 ship through limited distribution networks of 2-15 named pharmacies, so this single metric determines whether a pharmacy gets any revenue from a new molecule at all. Manufacturers select LDD partners 12-18 months before approval, meaning wins are locked before the drug has a J-code. Top national players sit in 70-85% of LDD networks; regionals target 30-50%.

This KPI is for commercial specialty pharmacy executives who control manufacturer trade relations and RFP strategy, not dispensing operations. It trades away short-term PBM network volume chasing in favor of 18-month manufacturer cultivation cycles. Compared to the fill rate KPI directly below it, LDD attach is upstream: fill rate keeps you on networks you already won, while LDD attach gets you onto the next one.

2Prescription Fill Rate KPI

Prescription fill rate by therapeutic category ranks second because it is the conversion metric that turns referrals into paid first fills within 14 days, and anything below 80% in a category signals broken prior auth, copay, or benefits verification upstream. Oncology runs hottest at 88-94% due to clinical urgency, infertility and HIV sit at 82-89%, and rare disease can drop to 70-78% during first launch year because of step therapy.

This KPI is for pharmacy operations directors tracking weekly performance by category, payer, and referring practice. It trades away simplicity, since a blended fill rate hides the category-level failures that actually cost LDD renewals. Compared to the time to first fill KPI below it, fill rate measures whether the script converts at all, while time to fill measures how fast that conversion happens.

3Time to First Fill KPI

Time to first fill ranks third because manufacturers contractually penalize LDD partners above 7 days median, and most hub contracts include a 5-day SLA with $5,000-$25,000 monthly penalties for misses. Best-in-class oncology pharmacies hit 2-4 days; rare disease with REMS and required lab values runs 5-10 days. The median target across categories is 3-7 days from referral receipt to shipped or picked up.

This KPI is for dispensing pharmacy managers and hub services leads who own the intake-to-shipment workflow. It trades away clinical consult depth, since faster turnaround means less pharmacist time per script. Compared to the prior authorization approval rate KPI below it, time to fill is the downstream outcome that PA speed directly controls, and appeals that add 5-9 days destroy this metric.

4Prior Authorization Approval Rate KPI

Prior authorization approval rate ranks fourth because first-pass approval at 78-88% is what hub contracts require, and pharmacies stuck at 55-68% on phone-and-fax workflows consistently miss SLAs. Strong performers use real-time benefits checks through CoverMyMeds, Surescripts Specialty, and ExpressPAth plus payer-specific PA templates. Appeals add 8-15 percentage points but cost an extra 5-9 days, destroying time-to-fill.

This KPI is for reimbursement and intake teams, plus the executives funding PA automation at $180,000-$420,000 implementation plus $40,000-$120,000 annual licensing. It trades away upfront capital for 4-9 month payback on hub SLA penalties avoided. Compared to the payer contract win rate KPI below it, PA approval is the operational proof point that supports winning the next contract bid.

5Payer Contract Win Rate KPI

Payer and PBM contract win rate ranks fifth because commercial specialty contracts are bid through 90-180 day RFP cycles run by Evernorth, CVS Caremark, OptumRx, Prime, and Blue Cross plans, and independents win only 12-18% of bids they enter. Integrated delivery network specialty pharmacies win 18-28% on regional bids through clinical integration, while national players win 22-35% on large national bids through geographic coverage.

This KPI is for VP of payer relations and business development leaders who own the RFP pipeline and track win rate by payer, geography, and therapeutic class. It trades away margin per script, since winning bids often requires competitive pricing concessions. Compared to the manufacturer hub attach rate KPI below it, payer win rate secures the network access that makes hub bids credible, but hub attach is what drives new molecule revenue.

6Manufacturer Hub Attach Rate KPI

Manufacturer hub attach rate ranks sixth because hub contracts pay $40-$180 per patient touch for prior auth handling, copay enrollment, nurse education, and adherence calls, and a pharmacy running hub services in-house captures both dispensing margin and patient services fees. Top 5 national players sit in 70-85% of LDD networks; regional players target 30-50% focused on a therapeutic class or geography. Below 25% attach means harvesting an aging book.

This KPI is for trade relations and patient services leaders deciding whether to build hub capabilities in-house or partner with AssistRx, TrialCard, Lash Group, ConnectiveRx, or Phil. It trades away operational simplicity, since in-house hub services require bilingual reimbursement specialists and nurse educators. Compared to the gross margin per script KPI below it, hub attach is the revenue layer that sits on top of dispensing margin.

7Gross Margin Per Script KPI

Gross margin per script ranks seventh because it varies wildly by category: oral oncology runs $180-$420 per fill, injectable biologics $380-$1,100, rare disease and gene therapy adjuncts $900-$2,400, and HIV maintenance $90-$220. Net margin after pharmacist labor, packaging, cold chain, hub fees, and DIR clawback runs 4-9% of revenue at the pharmacy level. PBM-owned pharmacies show lower per-script GM due to internal transfer pricing.

This KPI is for CFOs and finance teams modeling unit economics per therapeutic category and per payer contract. It trades away simplicity, since blended gross margin hides the categories that are actually profitable after DIR clawbacks. Compared to the patient adherence PDC KPI below it, gross margin measures the economics of each fill, while PDC measures whether those fills continue month over month.

8Patient Adherence PDC KPI

Patient adherence measured as proportion of days covered ranks eighth because PDC above 85% wins manufacturer adherence bonuses of $8-$45 per adherent patient per month and STAR-related payer contracts, while below 75% triggers manufacturer corrective action plans and risks LDD removal at renewal. Targets run 80-92% at 6 and 12 months on chronic therapies including HIV, MS, hepatitis C, autoimmune biologics, and oral oncology.

This KPI is for clinical operations and adherence teams who own refill reminder cadence, copay assistance retention, and nurse education contact frequency. It trades away script volume growth, since scaling adherence operations requires 1 FTE per 3,500-5,500 chronic patients. Compared to the accreditation maintenance cost KPI below it, PDC is the clinical outcome metric that manufacturers weigh most heavily in LDD renewal decisions.

9Accreditation Maintenance Cost KPI

Accreditation maintenance cost ranks ninth because URAC, ACHC, and JCAHO recertification is table stakes for any payer or manufacturer contract, and maintaining all three runs $180,000-$420,000 per location annually in audit prep, documentation systems, and pharmacist time. Cost scales per site, not per script, which pressures multi-site regional margins. Missing recertification by 30 days has caused pharmacies to lose 40-60% of payer network access.

This KPI is for quality and compliance leaders plus executives deciding whether to expand site count or consolidate accreditations. It trades away capital flexibility, since the annual spend is non-negotiable for staying on LDD lists. Compared to the revenue per pharmacist FTE KPI below it, accreditation is the fixed cost floor that productivity metrics must overcome to generate positive site-level EBITDA.

10Revenue Per Pharmacist FTE KPI

Revenue per dispensing pharmacist FTE ranks tenth because pharmacist productivity is the single biggest controllable cost lever, with best-in-class national platforms hitting $6.8M-$7.8M annually using ScriptMed Cloud, CPR+, or in-house dispensing systems plus technician extension. Regional independents run $4.2M-$5.4M due to less automation and more clinical consult time. Below $3.8M per FTE, unit economics break at any meaningful DIR clawback rate.

This KPI is for COOs and pharmacy operations leaders balancing automation investment against clinical staffing ratios. It trades away clinical depth, since higher revenue per FTE means less pharmacist time per patient consult. Compared to the accreditation maintenance cost KPI above it, revenue per FTE is the productivity counterweight that determines whether per-site fixed costs like accreditation translate into profitable scale.

How we ranked these

We ranked the nine commercial specialty pharmacy sales KPIs by weighting three factors: direct revenue impact, manufacturer and payer contract leverage, and controllability by the operator. LDD attach rate, prior authorization first-pass approval, and PDC carried the heaviest weight because they determine network inclusion. Fill rate, time to first fill, and gross margin per script followed. Accreditation cost and revenue per pharmacist FTE rounded out the list as structural constraints.

We deliberately ignored retail-style metrics such as script count growth, total revenue, and customer satisfaction scores. Volume growth without PDC above 85% triggers manufacturer corrective action and LDD removal, so it is a lagging trap. Revenue mixes dispensing margin with hub fees and hides per-script economics. Satisfaction surveys do not predict payer or manufacturer renewal. We also excluded DIR clawback estimates because disclosure varies too widely by contract to benchmark cleanly.

What to look for

When choosing between these KPIs, start with LDD attach rate if you pursue branded launches, because 65-75% of new specialty molecules ship through limited networks and no payer contract recovers that lost revenue. If your book is mature and generic-heavy, prioritize PDC and PA first-pass approval instead, since those protect existing manufacturer renewals. Match the KPI to your therapeutic mix, not to a national average.

The mistake most buyers make is adopting all nine KPIs at once with equal weight. That dilutes management attention and produces dashboards nobody acts on. A $300M regional should pick two or three KPIs tied to its next contract cycle, assign one owner each, and review weekly. National platforms can run all nine, but only with dedicated trade relations and payer relations teams feeding the data.

Related questions

What is a good LDD attach rate for a regional specialty pharmacy?

Regional specialty pharmacies typically target 30-50% attach on launches they actively pursue, focused on one therapeutic class or geography. National players sit at 70-85% because they appear in most manufacturer networks. Below 25% attach means you are locked out of new molecule revenue and harvesting an aging book. Track attach by manufacturer, not blended.

How fast should time to first fill be in 2027?

Median 3-7 days from referral to shipped medication. Oncology best-in-class hits 2-4 days. Rare disease with REMS and required labs runs 5-10 days. Most hub contracts include a 5-day SLA with $5K-$25K monthly penalties, and manufacturers penalize LDD partners above 7 days median. Measure median, not average, to avoid outlier distortion.

What PDC threshold protects manufacturer contracts?

Above 85% PDC on chronic therapies is the line that wins manufacturer adherence bonuses of $8-$45 per adherent patient monthly. Below 75% triggers corrective action plans and risks LDD removal at renewal. HIV, MS, and autoimmune biologics are watched closest. Allocate one adherence FTE per 3,500-5,500 chronic patients to hold the line as volume grows.

How much does PA automation cost and what does it return?

Implementation runs $180K-$420K plus $40K-$120K annual licensing through CoverMyMeds, ExpressPAth, Surescripts Specialty, or payer portal integrations. It moves first-pass approval from 55-68% to 78-88% and cuts median time to fill from 9-14 days to 3-7 days. Payback lands in 4-9 months on hub SLA penalties avoided and retained PA-denial revenue.

What gross margin per script should oncology specialty pharmacies expect?

Oral oncology runs $180-$420 per fill. Injectable biologics run $380-$1,100. Rare disease and gene therapy adjuncts run $900-$2,400. HIV maintenance runs $90-$220. Net margin after pharmacist labor, cold chain, hub fees, and DIR clawback lands at 4-9% of revenue. Track by category, because blended margin hides which lines are actually profitable.

How many manufacturer RFPs should an LDD bid team submit annually?

A dedicated team of three to six people should write 20-40 manufacturer RFPs per year, starting 18 months before each target molecule's PDUFA date. Top national players pursue every relevant launch. Regional players should target 8-15 bids concentrated in their therapeutic strength. Win rates of 20-35% on pursued bids are realistic with strong accreditation and hub capabilities.

What happens if URAC or ACHC recertification lapses?

Missing recertification by even 30 days has caused mid-sized pharmacies to lose 40-60% of payer network access at the next renewal cycle. Manufacturer audits remove lapsed pharmacies from LDD lists within 90 days. Remediation delays renewal 60-180 days. Run continuous accreditation operations with monthly internal audits and an 18-month rolling recertification calendar to avoid the scramble.

How is revenue per dispensing pharmacist FTE benchmarked?

National platforms with automation and technician extension hit $6.8M-$7.8M per pharmacist FTE annually. Regional independents run $4.2M-$5.4M because of less automation and more clinical consult time. Below $3.8M per FTE, unit economics break at any meaningful DIR clawback rate. This is the single biggest controllable cost lever in specialty pharmacy operations.

FAQ

What is the single most important specialty pharmacy KPI for 2027?

LDD attach rate. Because 65-75% of new specialty launches in 2026-2027 ship through limited distribution networks, your share of new revenue is determined by manufacturer LDD wins 12-18 months before launch. Fill rate, PA approval, and PDC keep you on networks you already won. LDD attach gets you onto the next one.

How do independents compete against CVS Specialty, Accredo, and Optum Specialty?

Three ways. Therapeutic class specialization, as Onco360 did in oncology. Health-system integration, where clinic-adjacent pharmacies share EMR access and oncologist relationships. Hub services depth, where independents running patient services in-house at higher quality win manufacturer attention despite PBM-owned competitors being pre-loaded into networks. Pure price competition against the big three is a losing game.

What is a realistic PA first-pass approval rate to target?

78-88% first-pass, 92-96% including appeals. Pharmacies stuck at 60-70% almost always have a workflow problem, not a clinical one: phone-and-fax PA, no payer-specific templates, no real-time benefits verification. Investing $180K-$420K in PA automation moves a $300M pharmacy from 65% to 82% first-pass in 4-7 months, paying back fast on hub SLA penalties avoided.

How much does accreditation actually cost per site?

$180K-$420K annually all-in to maintain URAC Specialty Pharmacy, ACHC Specialty Pharmacy, and JCAHO Home Care concurrently. Includes a dedicated quality FTE at $110K-$160K loaded, mock audit consulting at $40K-$80K per cycle, documentation systems, REMS compliance tracking, and pharmacist CE. Multi-site operators see scale benefits because cost scales per site, not per script.

Why is time to first fill more important than total script volume?

Manufacturers contractually penalize LDD partners above 7 days median time to fill, and hub contracts include 5-day SLAs with $5K-$25K monthly penalties. Slow fills also destroy PDC because patients abandon therapy during long waits. A pharmacy growing volume while time to fill drifts to 10 days will lose LDD contracts at renewal, erasing the volume gain entirely.

What adherence operations staffing ratio should we plan for?

One adherence FTE per 3,500-5,500 chronic specialty patients. That covers refill reminder calls, copay assistance retention, and nurse education touchpoints. Below that ratio, PDC drifts down 4-8 points within two quarters as volume grows. Above it, you are over-staffed relative to manufacturer adherence bonus economics of $8-$45 per adherent patient monthly.

How long is a typical commercial specialty payer RFP cycle?

90-180 days from RFP release to award, run by Evernorth, CVS Caremark, OptumRx, Prime, and Blue Cross plans. Independents win 12-18% of bids entered. Health-system specialty pharmacies win 18-28% on regional bids. National players win 22-35% on large national bids. Build a 12-month rolling RFP calendar because preparation starts well before release.

What is the fastest way to lift PDC by 3-5 points?

Fix copay assistance retention first. Most PDC drops trace to patients losing copay card coverage at month three or six and silently abandoning therapy. Automated copay re-enrollment, refill reminders timed to the copay reset, and nurse outreach at the 60-day mark typically lift PDC 3-5 points within two quarters without adding clinical staff.

Should we run hub services in-house or through a vendor?

In-house captures both the dispensing margin and the $40-$180 per patient touch hub fee, which is why hub attach rate is a primary KPI. Vendors like AssistRx, TrialCard, Lash Group, and ConnectiveRx offer faster launch but split the economics. Pharmacies that lose hub bids are usually under-staffed on bilingual reimbursement specialists, not under-priced. Build in-house once volume justifies two to four FTEs.

What reporting cadence keeps these KPIs from drifting?

Daily 15-minute standup on referrals, PA queue aging, and time-to-fill exceptions. Weekly 60-minute operations review on fill rate by category, hub SLA performance, and PA approval by payer. Monthly 90-minute manufacturer and payer review on LDD scorecards, hub fee revenue, PDC by molecule, and renewal pipeline. Quarterly half-day board review on RFP win rate, LDD attach, and revenue per pharmacist FTE.

Sources

• https://www.urac.org/accreditation-and-measurement/accreditation-programs/specialty-pharmacy/
• https://www.achc.org/programs/pharmacy/specialty-pharmacy/
• https://www.jointcommission.org/accreditation-and-certification/health-care-settings/home-care/
• https://www.naspnet.org/
• https://www.ashp.org/pharmacy-practice/resource-centers/specialty-pharmacy
• https://www.cms.gov/medicare/coverage/prescription-drug-coverage
• https://www.fda.gov/drugs/information-drug-class/limited-distribution-drugs
• https://www.pcmanet.org/
• https://www.cdc.gov/pharmacy/index.html

Related on PULSE

• More sales kpis for commercial specialty pharmacy rankings and buying guides
• PULSE Tools and calculators
• Everything on PULSE RevOps